A Phase 2 interventional study of Atacicept and Placebo matched to atacicept in Optic Neuritis, sponsored by EMD Serono. Terminated at 28 sites in 11 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2016-02-17.
Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Optic Neuritis with a site in United States — 5 open to participants now, 7 under way, 2 of them phase 3. Optic Neuritis · United States.
Among the 29 studies in Optic Neuritis with a site in United States, this one is the 12th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2008, is one of 4 in phase 2, and was the 7th registered.
88 studies on the registry are indexed under Optic Neuritis; 16 are open to participants now.
Browse Optic Neuritis studies →5 of the 29 studies in Optic Neuritis with a site in United States are open now. Recruiting first, the newest first:
Oculis · Sites in United States
Ages 18–50
Anastasia Vishnevetsky, MD, MPH · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecul · Sites in United States, Argentina, Australia and 14 more countries
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18–55
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Optic Neuritis studies recruiting now, 7 (50%) set no upper age limit and 6 (43%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 3 9 · Phase 4 3
First in 1988; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 50 across 58 interventional studies indexed under Optic Neuritis.
Median enrollment 43 across the 20 interventional studies, 131 across the 6 observational. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under EMD Serono, one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.
Merck KGaA, Darmstadt, Germany has 1 study filed under Optic Neuritis — fewer than ten, so there is no comparison to draw.
1 of the studies in Optic Neuritis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06453694Anastasia Vishnevetsky, MD, MPHEfgartigimod for the Treatment of Acute Optic Neuritis | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Optic Neuritis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study was intended to evaluate the efficacy, safety and tolerability of atacicept compared to placebo and to explore the neuroprotective effect of atacicept as assessed by OCT in subjects with ON as CIS. The study was randomized. Study medication was administered via subcutaneous (under the skin) injections.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Atacicept
Drug: Placebo matched to atacicept
Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
Change From Baseline in Retinal Nerve Fiber Layer (RNFL) Thickness in the Affected Eye at Last Observed Value (LOV)
The RNFL thickness was measured for 12 sectors (every 30 degrees) per eye in triplicate by optical coherence tomography (OCT) measurements and were then averaged over 12 sectors. The change in RNFL thickness at LOV visit was calculated as RNFL thickness at LOV minus RNFL thickness at baseline.
Time frame: Baseline, LOV (Week 48)
Difference in Retinal Nerve Fibre Layer (RNFL) Thickness Between the Affected Eye and Fellow Eye
The RNFL thickness was measured for 12 sectors (every 30 degrees) per eye in triplicate by optical coherence tomography (OCT) measurements and was then averaged over 12 sectors. Difference was calculated as RNFL thickness in affected eye minus RNFL thickness in fellow eye.
Time frame: Weeks 12, 24 and 36
Change From Baseline in Retinal Nerve Fiber Layer (RNFL) Thickness in the Affected Eye at Weeks 12 and 24
The RNFL thickness was measured for 12 sectors (every 30 degrees) per eye in triplicate by OCT measurements and was then averaged over 12 sectors. The change in RNFL thickness at Weeks 12 and 24 was calculated as RNFL thickness at Weeks 12 and 24 minus RNFL thickness at baseline, respectively.
Time frame: Baseline, Weeks 12 and 24
Change From Baseline in Macular Thickness at 3 Millimeter (mm) Around Fovea in the Affected Eye at Weeks 12, 24 and 36
The change in macular thickness at 3 mm around fovea in the affected eye at Weeks 12, 24 and 36 was calculated as macular thickness at 3 mm in the affected eye at Weeks 12, 24 and 36 minus macular thickness at 3 mm in the affected eye at baseline, respectively.
Time frame: Baseline, Weeks 12, 24 and 36
Change From Baseline in Macular Thickness at 6 Millimeter (mm) Around Fovea in the Affected Eye at Weeks 12, 24 and 36
The change in macular thickness at 6 mm around fovea in the affected eye at Weeks 12, 24 and 36 was calculated as macular thickness at 6 mm in the affected eye at Weeks 12, 24 and 36 minus macular thickness at 6 mm in the affected eye at baseline, respectively.
Time frame: Baseline, Weeks 12, 24 and 36
Change From Baseline in Macular Volume in the Affected Eye at Weeks 12, 24 and 36
The change in macular volume in the affected eye at Weeks 12, 24 and 36 was calculated as macular volume in the affected eye at Weeks 12, 24 and 36 minus macular volume in the affected eye at baseline, respectively.
Time frame: Baseline, Weeks 12, 24 and 36
Low-Contrast Letter Acuity: Total Number of Letters Correctly Identified
Low-contrast letter acuity was measured by using the Sloan Charts at 1.25 fraction (%) and 2.5%. Sloan letters are a set of optotypes used to test visual acuity. Total number of letters correctly identified in the affected and fellow eye were reported. The possible Sloan Chart range is 0 to 70. More the number of letters identified, better is the visual acuity.
Time frame: Weeks 12, 24 and 36
Contrast Sensitivity: Total Number of Letters Correctly Identified
Contrast Sensitivity was measured using the Pelli-Robson Charts. Pelli-Robson chart is used for clinical measurement of contrast sensitivity and determines the contrast required to read large letters of a fixed size. Total number of letters correctly identified in the affected and fellow eye were reported. The total possible range is 0 to 48. More the number of letters identified, better is the contrast sensitivity.
Time frame: Weeks 12, 24 and 36
Contrast Sensitivity: Score Line
Contrast sensitivity was measured using the Pelli-Robson charts with letters arranged in groups of 3. Pelli-Robson chart is used for clinical measurement of contrast sensitivity and determines the contrast required to read large letters of a fixed size. The possible score line range is 0 (visual disability) to 16 (normal contrast sensitivity).
Time frame: Weeks 12, 24 and 36
Percentage of Participants Converting to Clinically Definite Multiple Sclerosis (CDMS) Second Clinical Attack
Conversion to CDMS was defined as experiencing a second clinical attack meeting all of the following criteria: (a) Neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both (i) Neurological abnormality separated by at least 30 days from onset of a preceding clinical event, and (ii) Neurological abnormality lasting for at least 24 hours; (b) Absence of fever or known infection (fever with temperature \[axillary, orally or intraauricularly\] greater than 37.5 degree Celsius/99.5 degree Fahrenheit); (c) Objective neurological impairment, correlating with the participant's reported symptoms, defined as either (i) Increase in at least 1 of the functional systems of the Expanded Disability Status Score (EDSS), or (ii) Increase of the total EDSS score. EDSS assesses disability in 8 functional systems and total score ranges from 0 (normal) to 10 (death due to MS). Percentage of participants converting to CDMS (second clinical attack) was reported.
Time frame: From baseline (Study Day 1) up to Week 36
| Milestone | Placebo: Double-blind Period | Atacicept: Double-blind Period | Placebo: SFU Period | Atacicept: SFU Period |
|---|---|---|---|---|
| Started | 17 | 17 | 0 | 0 |
| Completed | 3 | 4 | 0 | 0 |
| Not completed | 14 | 13 | 0 | 0 |
| Withdrew: Early termination initiated by sponsor | 13 | 12 | 0 | 0 |
| Withdrew: Withdrew prematurely | 1 | 1 | 0 | 0 |
| Milestone | Placebo: Double-blind Period | Atacicept: Double-blind Period | Placebo: SFU Period | Atacicept: SFU Period |
|---|---|---|---|---|
| Started | 0 | 0 | 13 | 14 |
| Completed | 0 | 0 | 11 | 11 |
| Not completed | 0 | 0 | 2 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 2 |
| Withdrew: Other | 0 | 0 | 1 | 1 |
The RNFL thickness was measured for 12 sectors (every 30 degrees) per eye in triplicate by optical coherence tomography (OCT) measurements and were then averaged over 12 sectors. The change in RNFL thickness at LOV visit was calculated as RNFL thickness at LOV minus RNFL thickness at baseline.
| micrometer | Placebo: Double-blind Period | Atacicept: Double-blind Period |
|---|---|---|
| Baseline (n = 17, 17) | 103.893 ± 17.271 | 104.170 ± 8.832 |
| Change at LOV (n = 16, 15) | -17.317 ± 15.158 | -8.636 ± 10.056 |
The RNFL thickness was measured for 12 sectors (every 30 degrees) per eye in triplicate by optical coherence tomography (OCT) measurements and was then averaged over 12 sectors. Difference was calculated as RNFL thickness in affected eye minus RNFL thickness in fellow eye.
| micrometer | Placebo: Double-blind Period | Atacicept: Double-blind Period |
|---|---|---|
| Change at Week 12 (n = 13, 13) | -14 ± 4 | -7.9 ± 1.5 |
| Change at Week 24 (n = 4, 5) | -7 ± 6.9 | -10.6 ± 3.7 |
| Change at Week 36 (n = 3, 4) | -7.5 ± 8.8 | -9.4 ± 6.6 |
The RNFL thickness was measured for 12 sectors (every 30 degrees) per eye in triplicate by OCT measurements and was then averaged over 12 sectors. The change in RNFL thickness at Weeks 12 and 24 was calculated as RNFL thickness at Weeks 12 and 24 minus RNFL thickness at baseline, respectively.
| micrometer | Placebo: Double-blind Period | Atacicept: Double-blind Period |
|---|---|---|
| Baseline (n=17, 17) | 103.893 ± 17.271 | 104.170 ± 8.832 |
| Change at Week 12 (n = 13, 13) | -17.036 ± 13.919 | -9.356 ± 9.532 |
| Change at Week 24 (n = 4, 5) | -17.815 ± 16.505 | -11.234 ± 14.230 |
The change in macular thickness at 3 mm around fovea in the affected eye at Weeks 12, 24 and 36 was calculated as macular thickness at 3 mm in the affected eye at Weeks 12, 24 and 36 minus macular thickness at 3 mm in the affected eye at baseline, respectively.
| micrometer | Placebo: Double-blind Period | Atacicept: Double-blind Period |
|---|---|---|
| Baseline (n = 17, 17) | 1054.4 ± 76.5 | 1070.6 ± 72.7 |
| Change at Week 12 (n = 13, 13) | -29.3 ± 34.4 | -34.0 ± 21.8 |
| Change at Week 24 (n = 4, 5) | -72.5 ± 47.0 | -50.4 ± 47.7 |
| Change at Week 36 (n = 3, 4) | -32.7 ± 30.7 | -40.0 ± 51.3 |
The change in macular thickness at 6 mm around fovea in the affected eye at Weeks 12, 24 and 36 was calculated as macular thickness at 6 mm in the affected eye at Weeks 12, 24 and 36 minus macular thickness at 6 mm in the affected eye at baseline, respectively.
| micrometer | Placebo: Double-blind Period | Atacicept: Double-blind Period |
|---|---|---|
| Baseline (n = 17, 17) | 954.4 ± 57.4 | 947.5 ± 61.3 |
| Change at Week 12 (n = 13, 13) | -36.1 ± 28.4 | -32.8 ± 25.2 |
| Change at Week 24 (n = 4, 5) | -63.8 ± 32.7 | -46.2 ± 36.5 |
| Change at Week 36 (n = 3, 4) | -33.3 ± 33.7 | -34.8 ± 46.0 |
The change in macular volume in the affected eye at Weeks 12, 24 and 36 was calculated as macular volume in the affected eye at Weeks 12, 24 and 36 minus macular volume in the affected eye at baseline, respectively.
| cubic micrometer | Placebo: Double-blind Period | Atacicept: Double-blind Period |
|---|---|---|
| Baseline (n = 17, 17) | 6.8865 ± 0.4199 | 6.8794 ± 0.4372 |
| Change at Week 12 (n = 13, 13) | -0.2389 ± 0.1991 | -0.2301 ± 0.1612 |
| Change at Week 24 (n = 4, 5) | -0.4630 ± 0.2466 | -0.3292 ± 0.2674 |
| Change at Week 36 (n = 3, 4) | -0.2353 ± 0.2253 | -0.2533 ± 0.3205 |
Low-contrast letter acuity was measured by using the Sloan Charts at 1.25 fraction (%) and 2.5%. Sloan letters are a set of optotypes used to test visual acuity. Total number of letters correctly identified in the affected and fellow eye were reported. The possible Sloan Chart range is 0 to 70. More the number of letters identified, better is the visual acuity.
| letters | Placebo: Double-blind Period | Atacicept: Double-blind Period |
|---|---|---|
| Sloan chart 1.25%, affected eye: Week 12 (n=15,14) | 14.7 ± 14.7 | 15.7 ± 19.0 |
| Sloan chart 1.25%, affected eye: Week 24 (n = 5,5) | 16.2 ± 13.6 | 13.4 ± 18.4 |
| Sloan chart 1.25%, affected eye: Week 36 (n = 3,4) | 24.7 ± 8.1 | 9.8 ± 18.8 |
| Sloan chart 2.5%, affected eye: Week 12 (n=15, 14) | 25.6 ± 16.7 | 22.1 ± 19.5 |
| Sloan chart 2.5%, affected eye: Week 24 (n = 5, 5) | 26.8 ± 15.2 | 21.4 ± 19.3 |
| Sloan chart 2.5%, affected eye: Week 36 (n = 3, 4) | 38.7 ± 4.7 | 20.3 ± 18.7 |
| Sloan chart 1.25%, fellow eye: Week 12 (n=15,14) | 25.7 ± 13.1 | 25.9 ± 16.5 |
| Sloan chart 1.25%, fellow eye: Week 24 (n = 5,5) | 22.2 ± 16.1 | 24.6 ± 18.4 |
| Sloan chart 1.25%, fellow eye: Week 36 (n = 3,4) | 35.3 ± 4.2 | 19.8 ± 20.6 |
| Sloan chart 2.5%, fellow eye: Week 12 (n=15, 14) | 35.3 ± 13.4 | 36.4 ± 12.7 |
| Sloan chart 2.5%, fellow eye: Week 24 (n = 5, 5) | 33.6 ± 18.2 | 35.8 ± 15.4 |
| Sloan chart 2.5%, fellow eye: Week 36 (n = 3, 4) | 45.7 ± 4.5 | 32.5 ± 19.1 |
Contrast Sensitivity was measured using the Pelli-Robson Charts. Pelli-Robson chart is used for clinical measurement of contrast sensitivity and determines the contrast required to read large letters of a fixed size. Total number of letters correctly identified in the affected and fellow eye were reported. The total possible range is 0 to 48. More the number of letters identified, better is the contrast sensitivity.
| letters | Placebo: Double-blind Period | Atacicept: Double-blind Period |
|---|---|---|
| Affected eye: Week 12 (n = 15, 14) | 35.4 ± 5.9 | 32.4 ± 8.8 |
| Affected eye: Week 24 (n = 5, 5) | 34.2 ± 6.9 | 33.0 ± 4.7 |
| Affected eye: Week 36 (n = 3, 3) | 37.0 ± 5.3 | 34.7 ± 3.2 |
| Fellow eye: Week 12 (n = 15, 14) | 38.3 ± 4.1 | 37.6 ± 3.3 |
| Fellow eye: Week 24 (n = 5, 5) | 36.2 ± 9.4 | 37.4 ± 2.4 |
| Fellow eye: Week 36 (n = 3, 3) | 39.7 ± 4.0 | 40.0 ± 1.0 |
Contrast sensitivity was measured using the Pelli-Robson charts with letters arranged in groups of 3. Pelli-Robson chart is used for clinical measurement of contrast sensitivity and determines the contrast required to read large letters of a fixed size. The possible score line range is 0 (visual disability) to 16 (normal contrast sensitivity).
| units on a scale | Placebo: Double-blind Period | Atacicept: Double-blind Period |
|---|---|---|
| Affected eye: Week 12 (n = 15, 14) | 12.1 ± 1.5 | 10.9 ± 2.9 |
| Affected eye: Week 24 (n = 5, 5) | 11.4 ± 2.6 | 11.2 ± 1.6 |
| Affected eye: Week 36 (n = 3, 3) | 12.3 ± 2.1 | 11.7 ± 1.5 |
| Fellow eye: Week 12 (n = 15, 14) | 12.9 ± 1.5 | 12.7 ± 1.1 |
| Fellow eye: Week 24 (n = 5, 5) | 11.8 ± 3.3 | 12.4 ± 0.5 |
| Fellow eye: Week 36 (n = 3, 3) | 13.3 ± 1.2 | 13.3 ± 0.6 |
Conversion to CDMS was defined as experiencing a second clinical attack meeting all of the following criteria: (a) Neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both (i) Neurological abnormality separated by at least 30 days from onset of a preceding clinical event, and (ii) Neurological abnormality lasting for at least 24 hours; (b) Absence of fever or known infection (fever with temperature \[axillary, orally or intraauricularly\] greater than 37.5 degree Celsius/99.5 degree Fahrenheit); (c) Objective neurological impairment, correlating with the participant's reported symptoms, defined as either (i) Increase in at least 1 of the functional systems of the Expanded Disability Status Score (EDSS), or (ii) Increase of the total EDSS score. EDSS assesses disability in 8 functional systems and total score ranges from 0 (normal) to 10 (death due to MS). Percentage of participants converting to CDMS (second clinical attack) was reported.
| percentage of participants | Placebo: Double-blind Period | Atacicept: Double-blind Period |
|---|---|---|
| Percentage of Participants Converting to Clinically Definite Multiple Sclerosis (CDMS) Second Clinical Attack | 17.6 | 35.3 |
Collected over Baseline up to Week 48. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo: Double-blind Period | — | 0/17 (0%) | 14/17 (82.4%) |
| Atacicept: Double-blind Period | — | 0/17 (0%) | 16/17 (94.1%) |
| Placebo: SFU Period | — | 1/13 (7.7%) | 6/13 (46.2%) |
| Atacicept: SFU Period | — | 2/14 (14.3%) | 10/14 (71.4%) |
| Event | Placebo: Double-blind Period | Atacicept: Double-blind Period | Placebo: SFU Period | Atacicept: SFU Period |
|---|---|---|---|---|
| MyelitisNervous system disorders | 0/17 | 0/17 | 1/13 | 0/14 |
| PyrexiaGeneral disorders | 0/17 | 0/17 | 1/13 | 0/14 |
| BlisterSkin and subcutaneous tissue disorders | 0/17 | 0/17 | 1/13 | 0/14 |
| Bacterial pyelonephritisInfections and infestations | 0/17 | 0/17 | 0/13 | 1/14 |
| Multiple sclerosisNervous system disorders | 0/17 | 0/17 | 0/13 | 1/14 |
| Myelitis transverseNervous system disorders | 0/17 | 0/17 | 0/13 | 1/14 |
| Event | Placebo: Double-blind Period | Atacicept: Double-blind Period | Placebo: SFU Period | Atacicept: SFU Period |
|---|---|---|---|---|
| Injection site reactionGeneral disorders | 3/17 | 11/17 | 1/13 | 2/14 |
| HeadacheNervous system disorders | 3/17 | 4/17 | 0/13 | 2/14 |
| DizzinessNervous system disorders | 4/17 | 0/17 | 0/13 | 1/14 |
| DepressionPsychiatric disorders | 4/17 | 2/17 | 0/13 | 1/14 |
| Influenza like illnessGeneral disorders | 0/17 | 0/17 | 3/13 | 2/14 |
| FatigueGeneral disorders | 3/17 | 3/17 | 0/13 | 0/14 |
| Injection site haematomaGeneral disorders | 1/17 | 3/17 | 0/13 | 0/14 |
| DiarrhoeaGastrointestinal disorders | 3/17 | 2/17 | 0/13 | 0/14 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/17 | 1/17 | 2/13 | 0/14 |
| NasopharyngitisInfections and infestations | 2/17 | 1/17 | 0/13 | 2/14 |
Intent-to-treat (ITT) population included all randomized participants.
| Age, Continuous(years) | Placebo: Double-blind Period | Atacicept: Double-blind Period | Total |
|---|---|---|---|
| Mean | 32.3 ± 7.1 | 30.6 ± 10.2 | 31.4 ± 8.7 |
| Sex: Female, Male(Participants) | Placebo: Double-blind Period | Atacicept: Double-blind Period | Total |
|---|---|---|---|
| Female | 14 | 13 | 27 |
| Male | 3 | 4 | 7 |
The record gives a start of Jun 2008, a primary completion of Sep 2009 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2016, 6 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TACI receptor-IgG Fc fragment fusion protein